Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options
出版年份 2015 全文链接
标题
Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume 17, Issue 3, Pages 369-380
出版商
Informa Healthcare
发表日期
2015-11-12
DOI
10.1517/14656566.2016.1118055
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial
- (2015) Stephen J. Nicholls et al. AMERICAN HEART JOURNAL
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
- (2015) Dean J. Kereiakes et al. AMERICAN HEART JOURNAL
- Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
- (2015) Christie M. Ballantyne et al. AMERICAN JOURNAL OF CARDIOLOGY
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia
- (2015) Eliano Pio Navarese et al. ANNALS OF INTERNAL MEDICINE
- State of the art paper Lipid-lowering therapy in older persons
- (2015) Wilbert S. Aronow Archives of Medical Science
- Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
- (2015) Maciej Banach et al. Archives of Medical Science
- Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-ITCLINICAL PERSPECTIVES
- (2015) Erin A. Bohula et al. CIRCULATION
- Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials
- (2015) Costas Thomopoulos et al. CLINICAL CARDIOLOGY
- Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels
- (2015) Eli M. Roth et al. CLINICAL THERAPEUTICS
- Targeting PCSK9 for Therapeutic Gains
- (2015) Michael D. Shapiro et al. Current Atherosclerosis Reports
- Should we consider ezetimibe to reach even lower LDL-C targets?
- (2015) Aris P. Agouridis et al. CURRENT MEDICAL RESEARCH AND OPINION
- Using the concept of ideal cardiovascular health to measure population health
- (2015) Laura C. Maclagan et al. CURRENT OPINION IN CARDIOLOGY
- Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort
- (2015) Henna Cederberg et al. DIABETOLOGIA
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
- (2015) Christopher P. Cannon et al. EUROPEAN HEART JOURNAL
- PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
- (2015) Yuichi J. Shimada et al. EUROPEAN HEART JOURNAL
- Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
- (2015) Erik S. Stroes et al. EUROPEAN HEART JOURNAL
- Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology
- (2015) Michael M Page et al. Expert Opinion on Drug Metabolism & Toxicology
- Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
- (2015) Maciej Banach et al. Expert Opinion On Drug Safety
- Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials
- (2015) Chi-kin Ip et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Atherosclerosis: Recent trials, new targets and future directions
- (2015) Ricardo Ladeiras-Lopes et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Safety and efficacy of ezetimibe: A meta-analysis
- (2015) Gianluigi Savarese et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- New Therapies in the Treatment of High Cholesterol
- (2015) William H. Shrank et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease
- (2015) Ankur Pandya et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events
- (2015) Amit Pursnani et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Application of New Guidelines for the Primary Prevention of Atherosclerotic Cardiovascular Disease in a Korean Population
- (2015) Nan Hee Kim et al. Journal of Atherosclerosis and Thrombosis
- Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
- (2015) Harold Bays et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- High-density lipoprotein cholesterol, a protective or a risk factor for developing coronary heart disease? Tehran Lipid and Glucose Study
- (2015) Seyed Saeed Hashemi Nazari et al. Journal of Clinical Lipidology
- Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial
- (2015) Eliot A. Brinton et al. Journal of Clinical Lipidology
- Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
- (2015) Kenichi Tsujita et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both
- (2015) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
- (2015) G Kees Hovingh et al. LANCET
- Ezetimibe Stimulates Intestinal Glucagon-Like Peptide 1 Secretion Via the MEK/ERK Pathway Rather Than Dipeptidyl Peptidase 4 Inhibition
- (2015) Eugene Chang et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipids, blood pressure and kidney update 2014
- (2015) Maciej Banach et al. PHARMACOLOGICAL RESEARCH
- PCSK9 inhibition in patients with hypercholesterolemia
- (2015) Nihar R. Desai et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Efficacy and Safety of Alirocumab as Add-on Therapy in High-Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies
- (2015) Jennifer G. Robinson et al. CLINICAL CARDIOLOGY
- Effectiveness of Combination Therapy With Statin and Another Lipid-Modifying Agent Compared With Intensified Statin Monotherapy
- (2014) Kimberly A. Gudzune et al. ANNALS OF INTERNAL MEDICINE
- Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia
- (2014) Anastazia Kei et al. Archives of Medical Science
- Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
- (2014) Helen M Colhoun et al. BMC Cardiovascular Disorders
- Antihyperlipidemic Therapies Targeting PCSK9
- (2014) Michael Weinreich et al. Cardiology in Review
- Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
- (2014) John J. P. Kastelein et al. CARDIOVASCULAR DRUGS AND THERAPY
- Dysfunctional HDL: the journey from savior to slayer
- (2014) Corina Serban et al. Clinical Lipidology
- Can We Change the Functionality of HDL Cholesterol with Nonpharmacological and Pharmacological Agents?
- (2014) S. Dragan et al. CURRENT MEDICINAL CHEMISTRY
- Statins and New-Onset Diabetes
- (2014) Marcin Barylski et al. CURRENT PHARMACEUTICAL DESIGN
- Evolving targets for lipid-modifying therapy
- (2014) R. Q. Do et al. EMBO Molecular Medicine
- Letter to the Editor Atorvastatin in combination with ezetimibe and carotid atherosclerosis
- (2014) K.I. Paraskevas et al. GENETICS AND MOLECULAR RESEARCH
- Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial
- (2014) Eli M. Roth et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort
- (2014) Maryam Kavousi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Proprotein Convertase Subtilisin/Kexin 9 Inhibitors
- (2014) Simona Dragan et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary
- (2014) Terry A. Jacobson et al. Journal of Clinical Lipidology
- Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum
- (2014) Małgorzata Myśliwiec et al. Journal of Clinical Lipidology
- Application of New Cholesterol Guidelines to a Population-Based Sample
- (2014) Michael J. Pencina et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients
- (2014) D. Keene et al. BMJ-British Medical Journal
- Impact on Optical Coherence Tomographic Coronary Findings of Fluvastatin Alone Versus Fluvastatin + Ezetimibe
- (2013) Maoto Habara et al. AMERICAN JOURNAL OF CARDIOLOGY
- Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
- (2013) Mukul Sharma et al. ANNALS OF INTERNAL MEDICINE
- Lipid-Lowering Therapy in Persons With Chronic Kidney Disease
- (2013) Ashish Upadhyay et al. ANNALS OF INTERNAL MEDICINE
- State of the art paper Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease
- (2013) Beata Franczyk-Skóra et al. Archives of Medical Science
- Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study
- (2013) Vasilios G. Athyros et al. Archives of Medical Science
- Persistence with statin therapy in Hungary
- (2013) Zoltan Kiss et al. Archives of Medical Science
- Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia
- (2013) Michael J. Koren et al. CIRCULATION
- The Role of Fibrate Treatment in Dyslipidemia: An Overview
- (2013) Niki Katsiki et al. CURRENT PHARMACEUTICAL DESIGN
- PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
- (2013) Maciej Banach et al. CURRENT PHARMACEUTICAL DESIGN
- Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
- (2013) Manfredi Rizzo et al. CURRENT PHARMACEUTICAL DESIGN
- American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
- (2013) Paul Jellinger et al. Endocrine Practice
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
- (2013) B. G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- More Than a Billion People Taking Statins?
- (2013) John P. A. Ioannidis JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients
- (2013) Subroto Acharjee et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- An International Model to Predict Recurrent Cardiovascular Disease
- (2012) Peter W.F. Wilson et al. AMERICAN JOURNAL OF MEDICINE
- Editorial Lipid-lowering therapies and achievement of LDL-cholesterol targets
- (2012) Manfredi Rizzo et al. Archives of Medical Science
- Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials
- (2012) Doralisa Morrone et al. ATHEROSCLEROSIS
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
- (2012) Frederick Raal et al. CIRCULATION
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- (2012) David Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease
- (2012) Sotirios Tsimikas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
- (2012) Michael J Koren et al. LANCET
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
- (2012) Robert P Giugliano et al. LANCET
- Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?
- (2012) Aneta Otocka-Kmiecik et al. PROGRESS IN LIPID RESEARCH
- Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
- (2011) Uchechukwu K. Sampson et al. Current Atherosclerosis Reports
- Editorial [Carotid Intima-Media Thickness and Ezetimibe: The End of a Misunderstanding?]
- (2011) Kosmas I. Paraskevas et al. Current Vascular Pharmacology
- Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy
- (2011) David Preiss JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals
- (2011) Christiane L. Haase et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin
- (2011) David D. Waters et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
- (2011) Colin Baigent et al. LANCET
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
- (2010) Naveed Sattar et al. LANCET
- Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
- (2009) Allen J. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Loss-of-Function Mutations in the ABCA1 Gene With High-Density Lipoprotein Cholesterol Levels and Risk of Ischemic Heart Disease
- (2008) Ruth Frikke-Schmidt JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
- (2008) Anne B. Rossebø et al. NEW ENGLAND JOURNAL OF MEDICINE
- Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
- (2008) John J.P. Kastelein et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search